Sildenafil increases serum testosterone levels by a direct action on the testes

M Spitzer, S Bhasin, T G Travison, M N Davda, H Stroh, S Basaria, M Spitzer, S Bhasin, T G Travison, M N Davda, H Stroh, S Basaria

Abstract

Phosphodiesterase-5-inhibitors, such as sildenafil, increase intracavernosal cyclic guanosine monophosphate levels, which results in corporal smooth muscle relaxation and penile erection. Here, we determined the effects of sildenafil administration on the hypothalamic-pituitary-gonadal axis in men with erectile dysfunction and low testosterone levels. The Testosterone and Erectile Dysfunction trial (ClinicalTrials.gov # NCT00512707) initially administered an optimized dose of sildenafil to 140 men, aged 40-70 years with erectile dysfunction, low serum total testosterone (<11.4 nmol/L; 330 ng/dL) and/or free testosterone (<173 pmol/L; 50 pg/mL) over 3-7 weeks. Sex steroids and gonadotropins were measured at baseline and after sildenafil optimization in a longitudinal study without a separate control group. Serum testosterone, dihydrotestosterone (DHT) and oestrogens were measured using liquid chromatography-tandem mass spectrometry. Administration of an optimized dose of sildenafil was associated with mean increases of 3.6 nmol/L (103 ng/dL; p < 0.001) and 110 pmol/L (31.7 pg/mL; p < 0.001) in total and free testosterone levels respectively. This was accompanied by parallel increases in serum DHT (0.17 nmol/L; 4.9 ng/dL; p < 0.001) and oestradiol (14 pmol/L; 3.7 pg/mL; p < 0.001) and significant suppression of luteinizing hormone (change -1.3 units/L; p = 0.003) levels, suggesting a direct effect at the testicular level. Androstenedione and oestrone increased by 1.3 nmol/L (38 ng/dL; p = 0.011) and 10.7 pmol/L (2.9 pg/mL; p = 0.012), respectively, supporting a possible effect of sildenafil on adrenal steroidogenesis. In conclusion, sildenafil administration was associated with increased testosterone levels likely ascribable to a direct effect on the testis.

Keywords: erectile dysfunction; selective phosphodiesterase-5 inhibitors; sildenafil; testosterone.

© 2013 American Society of Andrology and European Academy of Andrology.

Figures

Figure 1
Figure 1
Hormonal changes with sildenafil therapy in men with low testosterone and erectile dysfunction. Mean hormone levels with 95% confidence intervals (CI) are displayed pre-and post-sildenafil therapy. Mean changes (95% CI; p-value), calculated using paired t-tests, are printed in each graph. The numbers of participants contributing to data at each time point are shown below the graphs.

Source: PubMed

3
S'abonner